Emcure Pharmaceuticals Limited (EMCURE) — Announcement | 12 August 2026
Emcure Pharmaceuticals reported strong Q1 FY27 results with 22.8% YoY revenue growth to INR 2,580 crore and 36.2% YoY PAT growth to INR 292 crore, driven by international expansion (34.2% growth) and resilient domestic growth (10.2%). Chairman Berjis Desai retired from the board to take a government role, while Satish Mehta assumed additional Chairman duties post-AGM and Samit Mehta was appointed new COO. The company acquired a 12.05% stake in Gennova, making it a 100% subsidiary. Management highlighted pipeline progress including 15+ approvals, anti-HPV and HIV licensing deals, and biosimilars focus under Samit Mehta's leadership, with FY27 revenue growth guidance of low to mid-teens and EBITDA margin expansion of 70-100 bps.
About Emcure Pharmaceuticals Limited (EMCURE)
Healthcare · Pharmaceuticals · Listed on NSE
📡 Get AI alerts when EMCURE files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track EMCURE — Free💡 Ask AI about this filing
📊 More EMCURE filings
- 🔴 Annual Report — 1 September 2026 Emcure Pharmaceuticals announced that it dispatched letters to shareholders without registered email...
- 🔴 Announcement — 1 September 2026 Emcure Pharmaceuticals announced a tentative investor meeting schedule for September 4, 2026 in Pune...
- 🔴 Announcement — 1 September 2026 CARE Ratings reaffirmed Emcure Pharmaceuticals' credit ratings with a Stable outlook, raising its lo...
- 🟡 Sustainability Report — 28 August 2026 Emcure Pharmaceuticals Limited submitted its Business Responsibility and Sustainability Report for F...
- 🔴 Annual Report — 28 August 2026 Emcure Pharmaceuticals' 2025-26 Annual Report (Reg. 34 (1)) filed on BSE on 28 August 2026, details ...
🔥 Also filed on 12 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when EMCURE files new disclosures
Track EMCURE filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track EMCURE — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd